{"entity":{"id":"flt3lg","kind":"target","name":"FLT3LG","aka":["fms related receptor tyrosine kinase 3 ligand","Fms-related tyrosine kinase 3 ligand"],"tldr":"FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","summary":"Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs).\n\nCIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Crenolanib, Ponatinib, Sunitinib and Lestaurtinib and others. Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.82, affected pathway 0.83, animal model 0.41, genetic association 0.00).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3766","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3766"},{"label":"UniProt P49771","url":"https://www.uniprot.org/uniprotkb/P49771/entry"},{"label":"NCBI Gene 2323","url":"https://www.ncbi.nlm.nih.gov/gene/2323"},{"label":"Ensembl ENSG00000090554","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090554"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 11 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FLT3LG","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3766","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3766","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P49771","url":"https://www.uniprot.org/uniprotkb/P49771/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FLT3LG","url":"https://civicdb.org/features/1937","note":"2 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000090554","url":"https://platform.opentargets.org/target/ENSG00000090554/associations","note":"association with cancer (MONDO_0004992) 0.53;  (GraphQL API, CC0)"}],"hgnc":"HGNC:3766","ensembl":"ENSG00000090554","uniprot":"P49771","entrez":"2323","biology":"Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs). Location: Cell membrane; Secreted (UniProt). Locus 19q13.33 (HGNC).","whereFound":["Acute myeloid leukaemia: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/flt3lg/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}]}}